Alice Hadchouel

Alice Hadchouel

Auto-generated profile, based on publicly available information

Alice Hadchouel

AP-HP, Hôpital Universitaire Necker-Enfants Malades, Service de Pneumologie Pédiatrique, Centre de Référence pour les Maladies Respiratoires Rares de l'Enfant, Paris, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2017 in Advances in Simulation
Verified
Journal Article
Open access
PDF file
DDDavid Drummond
David Drummond
AHAlice Hadchouel
Alice Hadchouel
ATAntoine Tesnière
Antoine Tesnière
Serious games are educational tools which are more and more used in patient and health professional education. In this article, we discuss three main points that developers and educators need to address during the development of a serious game for health. We first explain how to develop motivating serious games by finding a point where the intrinsic and extrinsic motivations of end users can converge. Then, we propose to identify the features of serious games which enhance their learning effectiveness on the basis of a framework derived from cognitive science and called “the four pillars of learning.” Finally, we discuss issues and solutions related to the evaluation of serious games.

15 August 2024 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CMCormac McCarthy
Cormac McCarthy
FBFrancesco Bonella
Francesco Bonella
MOMarissa O'CAllaghan
Marissa O'CAllaghan
CDClairelyne Dupin
Clairelyne Dupin
TATiago Alfaro
Tiago Alfaro
Elisabeth BendstrupElisabeth Bendstrup
Elisabeth Bendstrup
Background: Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by several distinct diseases leading to progressive dyspnoea, hypoxaemia, risk of respiratory failure and early death due to accumulation of proteinaceous material in the lungs. Diagnostic strategies may include computed tomography (CT) of the lungs, bronchoalveolar lavage (BAL), evaluation of antibodies against granulocyte–macrophage colony-stimulating factor (GM-CSF), genetic testing and, eventually, lung biopsy. The management options are focused on removing the proteinaceous material by whole lung lavage (WLL), augmentation therapy with GM-CSF, rituximab, plasmapheresis and lung transplantation. The presented diagnostic and management guidelines aim to provide guidance to physicians managing patients with PAP.Methods: A European Respiratory Society Task Force composed of clinicians, methodologists and patients with experience in PAP developed recommendations in accordance with the ERS Handbook for Clinical Practice Guidelines and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. This included a systematic review of the literature and application of the GRADE approach to assess the certainty of evidence and strength of recommendations. The Task Force formulated five PICO (Patients, Intervention, Comparison, Outcomes) questions and two narrative questions to develop specific evidence-based recommendations.Results: The Task Force developed recommendations for the five PICO questions. These included management of PAP with WLL, GM-CSF augmentation therapy, rituximab, plasmapheresis and lung transplantation. Also, the Task Force made recommendations regarding the use of GM-CSF antibody testing, diagnostic BAL and biopsy based on the narrative questions. In addition to the recommendations, the Task Force provided information on the hierarchy of diagnostic interventions and therapy.Conclusions: The diagnosis of PAP is based on CT and BAL cytology or lung histology, whereas the diagnosis of specific PAP-causing diseases requires GM-CSF antibody testing or genetic analysis. There are several therapies including WLL and augmentation therapy with GM-CSF available to treat PAP, but supporting evidence is still limited.

9 September 2021 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
AHAlice Hadchouel
Alice Hadchouel
DDDavid Drummond
David Drummond
CPClément Pontoizeau
Clément Pontoizeau
LALaura Aoust
Laura Aoust
MNMaria-Margarita Hurtado Nedelec
Maria-Margarita Hurtado Nedelec
CDChristophe Delacourt
Christophe Delacourt
Introduction: Pulmonary alveolar proteinosis related to mutations in the methionine tRNA synthetase (MARS1) gene is a severe, early-onset disease that results in death before the age of 2 years in one-third of patients. It is associated with a liver disease, growth failure and systemic inflammation. As methionine supplementation in yeast models restored normal enzymatic activity of the synthetase, we studied the tolerance, safety and efficacy of daily oral methionine supplementation in patients with severe and early disease.Methods: Four patients received methionine supplementation and were followed for respiratory, hepatic, growth and inflammation-related outcomes. Their course was compared to those of historical controls. Reactive oxygen species production by patient monocytes before and after methionine supplementation was also studied.Results: Methionine supplementation was associated with respiratory improvement, clearance of the extracellular lipoproteinaceous material and discontinuation of whole-lung lavage in all patients. The three patients who required oxygen or noninvasive ventilation could be weaned off within 60 days. In addition, liver dysfunction, inflammation and growth delay improved or resolved. At a cellular level, methionine supplementation normalised the production of reactive oxygen species by peripheral monocytes.Conclusion: Methionine supplementation was associated with important improvements in children with pulmonary alveolar proteinosis related to mutations in theMARS1gene. This study paves the way for similar strategies for other tRNA synthetase deficiencies.

4 July 2024 in Thorax
Verified
Journal Article
Closed access
PDF file
CFCamille Fletcher
Camille Fletcher
AHAlice Hadchouel
Alice Hadchouel
CTCaroline Thumerelle
Caroline Thumerelle
JMJulie Mazenq
Julie Mazenq
MFManon Fleury
Manon Fleury
NNNadia Nathan
Nadia Nathan
Introduction Interstitial lung disease in children (chILD) are rare and mostly severe lung diseases. Very few epidemiological data are available in limited series of patients. The aim of this study was to assess the prevalence and incidence of chILD in France. Methods We performed within the RespiRare network a multicentre retrospective observational study in patients with chILD from 2000 to 2022 and a prospective evaluation of chILD’s incidence between February 2022 and 2023. Results chILD was reported in 790 patients in 42 centres. The estimated 2022 prevalence in France was 44 /million children (95% CI 40.76 to 47.46) and the computed incidence was 4.4 /million children (95% CI 3.44 to 5.56). The median age at diagnosis was 3 months with 16.9% of familial forms. Lung biopsy and genetic analyses were performed in 23.4% and 76.9%, respectively. The most frequent chILD aetiologies in the <2 years group were surfactant metabolism disorders (16.3%) and neuroendocrine cell hyperplasia of infancy (11.8%), and in the 2–18 years group diffuse alveolar haemorrhage (12.2%), connective tissue diseases (11.4%), hypersensitivity pneumonitis (8.8%) and sarcoidosis (8.8%). The management included mainly oxygen therapy (52%), corticosteroid pulses (56%), oral corticosteroids (44%), azithromycin (27.2%), enteral nutrition (26.9%), immunosuppressants (20.3%) and hydroxychloroquine (15.9%). The 5-year survival rate was 57.3% for the patients diagnosed before 2 years and 86% between 2 and 18 years. Conclusion This large and systematic epidemiological study confirms a higher incidence and prevalence of chILD than previously described. In order to develop international studies, efforts are still needed to optimise the case collection and to harmonise diagnostic and management practices.

10 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAlice Hadchouel
Alice Hadchouel
LMLaetitia Marchand-Martin
Laetitia Marchand-Martin
MFMarie-Laure Franco-Montoya
Marie-Laure Franco-Montoya
LPLaetitia Peaudecerf
Laetitia Peaudecerf
PAPierre-Yves Ancel
Pierre-Yves Ancel
EGEPIPAGEADO study group
EPIPAGEADO study group
Preterm birth is associated with abnormal respiratory functions throughout life. The mechanisms underlying these long-term consequences are still unclear. Shortening of telomeres was associated with many conditions, such as chronic obstructive pulmonary disease. We aimed to search for an association between telomere length and lung function in adolescents born preterm. Lung function and telomere length were measured in 236 adolescents born preterm and 38 born full-term from the longitudinal EPIPAGE cohort. Associations between telomere length and spirometric indices were tested in univariate and multivariate models accounting for confounding factors in the study population. Airflows were significantly lower in adolescents born preterm than controls; forced expiratory volume in one second was 12% lower in the extremely preterm born group than controls (p<0.001). Lower birth weight, bronchopulmonary dysplasia and postnatal sepsis were significantly associated with lower airflow values. Gender was the only factor that was significantly associated with telomere length. Telomere length correlated with forced expiratory flow 25–75 in the extremely preterm adolescent group in univariate and multivariate analyses (p = 0.01 and p = 0.02, respectively). We evidenced an association between telomere length and abnormal airflow in a population of adolescents born extremely preterm. There was no evident association with perinatal events. This suggests other involved factors, such as a continuing airway oxidative stress leading to persistent inflammation and altered lung function, ultimately increasing susceptibility to chronic obstructive pulmonary disease.

13 December 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
AGApolline Gonsard
Apolline Gonsard
RARola AbouTaam
Rola AbouTaam
BPBlandine Prévost
Blandine Prévost
CRCharlotte Roy
Charlotte Roy
AHAlice Hadchouel
Alice Hadchouel
DDDavid Drummond
David Drummond